ArticleFrontiers in pharmacology2026
Putative identification of CASTOR1 as one of the targets of ganoderic acid a via thermal proteome profiling and molecular docking.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Traditional Chinese Medicine Formulas in Delaying Aging: From Theoretical Foundations to Molecular Mechanisms and Translational Perspectives.Journal of cellular and molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In traditional Chinese medicine theory, aging is hypothesized to arise from severe deficiency of kidney essence, which is posited to induce "emptiness of the sea of marrow". Ganoderma has been documented to possess properties that nourish kidney qi and enrich essence and blood. It has been demonstrated that ganoderma triterpenoids are capable of mitigating age-related cerebral atrophy and retarding the aging process in murine models. Ganoderic acid A (GAA) has been characterized as the principal bioactive metabolite of these triterpenoids. Leveraging thermal proteomics profiling, CASTOR1 was identified as a target protein exhibiting significant disparities in melting curves. Through functional annotation via GO terms and pathway analysis using KEGG, it has been indicated that GAA may modulate metabolic regulatory pathways through interaction with specific molecular targets. A pronounced association between GAA and the GATOR2 complex, a downstream effector of CASTOR1, has been revealed by GO enrichment analysis, suggesting a potential mechanistic link. Thus, it is inferred that one potential target of GAA in neuronal cells is presumably CASTOR1 protein. It is hypothesized that ganoderic acid A exerts its pharmacological effects likely through regulation mediated by the potential target protein CASTOR1, which in turn modulates the mTOR signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.